Last reviewed · How we verify

NCT05708040: EBIACE-1

Clinical Trial to Evaluate the Efficacy of the Smart Insulin Pen Compared to a Closed Loop System in Patients With Type 1 Diabetes (EBIACE-1)

Completed NA Last updated 26 March 2024
What this trial tests

NA trial testing InPen Medtronic in Type1diabetes in 48 participants. Completed in 27 January 2023.

Timeline
19 August 2022
Primary endpoint
27 January 2023
27 January 2023

Quick facts

Lead sponsorFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment48
Start date19 August 2022
Primary completion27 January 2023
Estimated completion27 January 2023
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Who can join

18 and older, any sex, with Type1diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analysis of glycemic control, frequency of hypoglycemia, glycemic variability, patient satisfaction and patient-perceived quality of life in patients with type 1 diabetes mellitus and continuous real-time glucose monitoring, the use of a smart pen compared to a closed loop system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type1diabetes

Currently open trials in the same condition.

Other Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05708040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing